Kornimate/medical-research-clean huggingface dataset:
swc for treatment of superficial partial-thickness burns

Conditions: Burn Wounds

Summary: the purpose of this study is to test the safety and effectiveness of synepure™ wound cleanser when used in combination with catasyn™ advanced technology hydrogel for the treatment of superficial partial-thickness burn wounds.

current management options for burn wounds contain silver (nanoparticulate or ionic), hypochlorite, hydrogen peroxide, sulfa agents, chlorhexidine, iodine or other dilute antiseptics meant to provide some measure of antimicrobial protection. however, all of these materials have some proven limitations in facilitating wound healing and also have notable local and systemic adverse effects. none of the current clinical treatments enhance healing and/or reduce scar formation. the purpose of this study is to test the safety and effectiveness of synepure™ wound cleanser when used in combination with catasyn™ advanced technology hydrogel for the treatment of superficial partial-thickness burn wounds. this study is a prospective, parallel group, randomized controlled trial comparing synepure wound cleanser and catasyn advanced technology hydrogel (intervention group) to routine care, silvadene (control group). both groups will receive the same care other than the treating agent. subjects will be recruited from the burn center/clinic adult patient pool who have sustained superficial partial-thickness burn wounds that comprise ≤15% of total body surface area (tbsa).

Eligibility criteria:
inclusion criteria: * patients who have sustained superficial, partial thickness burn wounds no less than 5% and up to 15% of total body surface area (tbsa; 5-15%). contiguous superficial and deep partial-thickness burns are eligible for inclusion. * patients otherwise in good general physical and mental health, as per the investigator's clinical judgment. exclusion criteria: * inability to provide informed consent * deep partial-thickness burns except as noted in the inclusion criteria and full-thickness burns * radiation, chemical or electrical burn injury * patients with burns primarily located to the face, genitals, or span across joints * patients whose burn injury was ≥ 8 days prior to entry into the burn center/ clinic. * patients with uncontrolled cerebrovascular disease, cardiovascular disease, concurrent endocrine, hepatic or renal disease, or other severe conditions for whom, in the investigators' discretion would render study participation unsafe * patients with documented or self-reported shellfish allergies * current pregnancy * patients with concurrent burn related injuries or inhalation injury that would put the patient at increased risk, per physician discretion * any condition to which in the investigator's discretion would render study enrollment a safety concern for the patient.
blood flow restriction resistance exercise in lower cervical spinal cord injury patients

Conditions: Cervical Spinal Cord Injury

Summary: this study is conducted to investigate the effects of low load blood flow resistance exercise to improve strength and transfer in lower cervical spinal cord injury patientscervical spinal cord injury patients have very less window of opportunity towards functional mode of life. in complete cervical spinal cord injuries only few muscles of upper limb are completely innervated and it is a need to gain maximum output and advantage out of that. through conventional strength training it is possible to make him do unsupported sitting and transfer but with bfr-re it may have a possibility to do this procedure in less time than the conventional strength training and patient will save cost of hospital stay as he may timely discharge from hospital early


Eligibility criteria:
inclusion criteria: * both male and female, with age between 16-50 years. * patients evaluated with c6 to c8 tetraplegic complete injury. * patients classified in asia a, asia b. * at least muscle grading of grade 2. * patients with sub-acute, chronic stage. exclusion criteria: * patients with other neurologic conditions, orthopedic problems, and uncontrolled metabolic diseases. * patients with muscles strength grading of less than 2. * undergone nerve transfer surgery. * patients with acute stage. * history of dvt. * patients who are already performing structured physical activities such as muscle strengthening exercises.
clinical evaluation of a new printable denture base material

Conditions: Edentulous Mouth

Summary: this clinical investigation is conducted to prove the long-term clinical performance of a new printable denture base material. the aim of this study is to assess the failure rate, the quality and functionality of the full dentures made with the printable denture base material over an investigational period of 5 years.


Eligibility criteria:
inclusion criteria: * age: 18 to 84 years * informed consent signed and understood by the subject * full edentulous patients * a digital design of the dentures is already existing. * ability to visit the clinic in person until the baseline recall exclusion criteria: * patient does not wear the dentures regularly * mental health status does not allow reliable feedback * patients with a proven allergy to one of the ingredients (methacrylates) of the materials used * patients with severe systemic diseases * poor oral / denture hygiene * pregnancy
role of dutasteride in patients undergoing 3d mapping biopsy in early stage prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the effect of short-term intake of daily dutasteride in patients with prostate cancer.

this is a study of men who have undergone a standard 10 or more core biopsy for detection of prostate cancer and determined to have prostate cancer by having a gleason score ≤ 7 (low to moderate risk 2-7). of these men, one arm of a two arm randomized group will be administered a treatment regime of dutasteride versus the control group who receive standard of care, prior to mapping biopsy. this proposal aims at studying the apparent effect of the use of dutasteride (3 months) on initial tumor volume (at diagnosis) in men with low volume cancer before undergoing 3d mapping biopsy.

Eligibility criteria:
inclusion criteria: * 40-85 year old males * patient is newly diagnosed with clinical stage t1a-t2c prostate cancer based on transrectal guided extended prostate biopsy of at least 10 cores. * patient elects to undergo 3d mapping biopsy at our center as part of prostate cancer management. * patient will read, understand and sign the informed consent agreement * patients must have a life expectancy of at least one year. * gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4 * percentage positive core rate \< 50% based on sextant or extended biopsy technique. * prostate volume (pv) \>15 grams. * negative imaging studies ( if available) during the staging period such as bone scan, mri and ct scan if psa\> 10 ng.dl before initiation of the study drug exclusion criteria: * any 5α-reductase inhibitors medications within the past 12 months before enrollment. * known hypersensitivity to dutasteride, or other 5α-reductase inhibitors. * anticipated blood donation within the next 90 days. * serum psa levels of \>20ng/dl. * clinical evidence of metastatic prostate cancer. * two documented urinary tract infections in the past year * chf, mi (within 6 months) or other symptomatic cvs disease * other serious diseases (hematological, hepatic, renal, respiratory or psychiatric) * enrollment in other studies for any disease in the past 30 days * significant urinary incontinence * diagnosis of cancer that in not considered cured, except bcc of skin * prior transurethral resection of the prostate with a large tissue defect. * history of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology * previous or concurrent radiotherapy, hormonal therapy or chemotherapy

Keywords: prostate cancer early stage prostate cancer
cross-sectional study of prevalence rate of abdominal aortic aneurysm in osahs patients from btch

Conditions: Sleep Apnea, Obstructive; AAA - Abdominal Aortic Aneurysm

Summary: this study explore aaa prevalence in osahs patients by ultrasound screening and try to analysis risk factors of aaa in osahs patients.

abdominal aortic aneurysm (aaa) is an extremely high mortality disease, and ultrasound has been recommended for the screening of aaa, which is highly sensitive and specific. studies have shown that screening for aaa in the population can significantly reduce deaths from ruptured abdominal aortic aneurysms. however, those study mainly focus on cardiovascular disease patients or general population, no previous study target on obstructive sleep apnea hypopnea syndrome (osahs) population. retrospective studies show that the incidence of apnea syndrome in patients with abdominal aortic aneurysm is higher than that in the control group, which suggests that osahs may be one of the causes of abdominal aortic aneurysm. at present, there is no relevant research on the screening of aaa in osahs population. the main objective of this study was to screen the prevalence of aaa in osahs population by a cross-sectional study.

Eligibility criteria:
inclusion criteria: * all patients who accept respiratory sleep monitoring in the department of ent, btch, aged over 45 years, from 2018-01-01 to 2019-12-30 exclusion criteria: * 1. any previous diagnosis of aaa history; * 2. received aaa related treatment; * 3. past imaging test result suggested increased diameter of the abdominal aorta. * 4. poor compliance; refused to follow the requirements set in this study follow-up, and refused to sign informed consent.
phase ii trial of carbon-ion radiotherapy combined with gm-csf for the treatment of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the aim of this research project is to assess the efficacy and toxicity of hypofractionated carbon-ion radiotherapy with concurrent granulocyte-macrophage colony-stimulating factor for the treatment of hepatocellular carcinoma

golden e.b. et al.in 2015 reported that localized radiotherapy granulocyte-macrophage colony-stimulating factor (gm-csf) produced objective abscopal responses in solid tumor with metastasises. we hypothesize that hypofractionated carbon-ion radiotherapy combining granulocyte-macrophage colony-stimulating factor (gm-csf) might improve the clinical response rate and progression-free survival (pfs) in hepatocellular carcinoma. the primary endpoint of the current phase ii trial is progression-free survival rate at 2 years, secondary endpoints are overall survival, safety and toxicity.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed hepatocellular carcinoma (hcc) or clinical diagnosis of hcc according to american association for the study of liver diseases （aasld）-guidelines or clinical diagnosis criteria based on alpha fetoprotein （afp), and radiological images proposed by liver cancer society, chinese anti-cancer association; 2. no clinically distant metastasis; 3. the tumor is away from gastro-intestinal (gi) tract (\>1cm); 4. child push score a,technically unresectable, or medically inoperable; maximal tumor size is less than 10 cm; 5. age ≥ 18 and \<80 years of age; 6. karnofsky performance score ≥ 70; 7. no previous invasive cancer (within 5 years before the hcc diagnosis)except for skin non-melanoma cancer or non muscle invasive bladder cancer; ability to understand character and individual consequences of the clinical trial; 8. willing to sign the written informed consent; informed consent must be signed before the enrollment in the trial; exclusion criteria: 1. distant metastasis (m1); 2. maximal tumor size is more than 10 cm; 3. tumor invading adjacent gastrointestine (t4); 4. child push score b or c; 5. previous hepatic radiotherapy; 6. severe systemic disorders; 7. previous malignancy (within 5 years) except for skin non-melanoma cancer or 3-year disease free interval from previous malignancy like in situ cervix cancer or non muscle invasive bladder cancer; 8. non conformity of the radiotherapy dose distribution when compared to the dose constraints; 9. psychiatric disorders or any other condition that can make unreliable the informed consent;

Keywords: hepatocellular carcinoma carbon-ion radiotherapy gm-csf immunotherapy
examining the effects of neural stimulation on inhibitory control and cigarette smoking

Conditions: Tobacco Use Disorder

Summary: the purpose of this research study is to examine the effects of theta-burst transcranial magnetic stimulation on inhibitory control and smoking among adult cigarette smokers.


Eligibility criteria:
inclusion criteria: 1. be between the ages of 18 and 65. 2. be in stable mental and physical health. 3. be willing to provide informed consent. 4. be able to comply with protocol requirements and likely to complete all study procedures. 5. be a current nicotine dependent cigarette smoker (smoke ≥10 cigs/day) with a minimum smoking history of smoking an average of ≥ 10 cigs/day over the past two years. exclusion criteria: * 1. contraindication to mri (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia). 2. contraindication to tms (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy, as indicated by a positive urine pregnancy test at screening). 3. any use of substances that lower seizure threshold (such as thyroid medications or cocaine). 4. history of autoimmune, endocrine, viral, or vascular disorder affecting the brain. 5. history or mri evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. 6. unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea. 7. bac greater than 0.0. 8. any other condition or concern that in the investigator's opinion would impact participant safety, compliance with study instructions, or potentially confound the interpretation of the study results.
cardiac output monitoring in aortic aneurysm surgery

Conditions: Aneurysm

Summary: to compare co values obtained by the lithium indicator dilution method and pulse power analysis before, during and after anaesthesia and surgery for the elective repair of abdominal aortic aneurysms. this will enable us to determine how often and when calibration of the pulse power analysis derived co is required.


Eligibility criteria:
inclusion criteria: * patients presenting for elective abdominal aortic and extent 4 thoracoabdominal aortic aneurysm repair exclusion criteria: * patients not giving informed consent. * patients under the age of 18 years. * patients who may be pregnant * patients with learning disabilities. * rhythm other than sinus rhythm. * patients on oral lithium therapy. * patients less than 40kg * patients with severe mitral regurgitation

Keywords: aortic aneurysm repair
trial of enzastaurin and bevacizumab in participants with recurrent malignant gliomas

Conditions: Recurrent Glioblastoma

Summary: the purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.


Eligibility criteria:
inclusion criteria: * participant must be at least 18 years old * participant must have been diagnosed with a recurrent brain tumor by magnetic resonance imaging (mri) scan * participant must be willing to practice adequate contraception * participant must be able to swallow the enzastaurin tablets whole and receive bevacizumab intravenously * participant must agree to use the study drug only as instructed by your study doctor and staff. exclusion criteria: * women who are pregnant or breastfeeding * participants who have significant heart, liver, kidney, or psychiatric disease * participants who have an active infection * participants who have any recent bleeding in the brain * participants who are taking any anti-coagulation or anti-platelet medication \[including aspirin, non-steroidal anti-inflammatories, cyclooxygenase-2 (cox-2) inhibitors\]
aml1-eto acute myeloid leukemia with fludarabine and cytarabine chemotherapy

Conditions: Acute Myeloid Leukemia; AML1-ETO Fusion Protein Expression

Summary: the purpose of the study is to determine whether fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with aml1-eto acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: * clinical and laboratory diagnosis of aml1-eto positive acute myeloid leukemia * in status of complete remission after one to two courses of induction therapy with da(daunorubicin 60mg/m2/d for 3 days, cytarabine 100mg/m2/d for 5-7days) regimen * ecog (eastern cooperative oncology group) score: \<2 exclusion criteria: * serious liver/ kidney dysfunction * cardiac function level: 2 above * female in pregnancy or lactation * with serious infection diseases or other diseases

Keywords: acute myeloid leukemia, aml1-eto fusion protein, fludarabine, recurrence
role of peripheral vision in scene perception (perisce)

Conditions: Primary Open-angle Glaucoma (POAG)

Summary: despite its low spatial resolution, peripheral vision is very useful for rapidly categorizing a visual scene. low spatial frequencies of a visual stimulus available in peripheral vision would allow a coarse categorization of the scene and objects (deciding, for example, whether it is an urban or natural landscape). this first representation would then trigger predictive mechanisms which would subsequently guide a more detailed visual analysis in central vision. the psychophysical studies that the investigators have already conducted in this scientific context has been carried out under normal vision conditions. the objective of this project is to study the influence of peripheral vision on central vision with an original approach: what are the consequences of a loss of peripheral vision on the processing performed in central vision? the project will concern patients with glaucoma. this ophthalmic pathology particularly affects the peripheral retina and thus represents a good pathological cognitive model of a visual recognition system in which peripheral vision is less important. the investigators will conduct psychophysical studies with glaucomatous patients and healthy volunteers with normal vision. all participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. participants will have to perform various tasks on these images using the keys on the keyboard.


Eligibility criteria:
inclusion criteria: for patients : * between 18 and 80 years old * stable bilateral primary open angle glaucoma (poag) * visual acuity \> 5/10 for distant vision for the eye tested * peripheral visual field defect on the eye tested measured through a humphrey visual field analyzer for healthy volunteers : * between 18 and 80 years old * visual acuity \> 5/10 * absence of ophthalmologic disease other than glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy ...) exclusion criteria: * ophthalmologic disease other than glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy ...) * treated with medication that might compromise sustained attention (benzodiazepine, narcoleptics)
a study of silmitasertib (cx-4945) in healthy subject

Conditions: COVID-19

Summary: this is a phase i single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of cx-4945 200mg qd, 200 mg bid and 400mg bid doses (10 subjects in each regimen) for continuously 5 days in healthy subjects for dose selection.

covid-19 is characterized by sars-cov-2 induced up-regulation of host protein kinase ck2 that catalyzes phosphorylation of many proteins, modulating their activities in cellular processes. cx-4945 demonstrated anti-viral efficacy in covid-19 in vitro studies. in cx4945-av01-iit(ind 152726), cx-4945 was a safe treatment at 1000 mg bid regimen supported by the fact of no occurrence of treatment related grade ≥ 3 ae, death or susar. there were approximately 50 % of patients who experienced gastrointestinal disorders of grade 1-2. in cx4945-av01-iit, an out-patient study, there were 50% experienced gastrointestinal disorders. to further evaluate the safety and tolerability of cx-4945, this phase 1 study will use lower doses and subjects will be close-monitored to evaluate the safety.

Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects 20to 55 years of age, inclusive, at screening 2. body mass index (bmi)within the range of 18.0 to 30.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at screening 3. subjects who are of reproductive potential agreed to remain abstinent or use (or have their partner use) an acceptable method of birth control (intrauterine device, hormonal contraception, vasectomy or condom) from screening until at least 2 weeks after the last study drug administration. 4. physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, and electrocardiogram; 5. subject with acceptable hematology, biochemistry and urinalysis during screening period. 6. subject is willing and able to comply with study procedures and sign informed consent. exclusion criteria: 1. pregnant or nursing women. note: women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and from screening until at least 2 weeks after the last study drug administration. should a man father a child, or a woman become pregnant or suspect she is pregnant while participating in this study, he or she should inform the treating physician immediately. 2. active or uncontrolled infections such ascovid-19, hiv or with serious illnesses or medical conditions which would not permit the subject to receive study treatment. 3. subject has received any prescription of drug within 3 days prior to study enrollment. 4. subject has drug abuse history. 5. any active or recurring clinically significant hepatic disease including hbv and hcv. 6. subject has received any investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product. 7. any other medical reason as determined by the investigator.